Acurx Pharmaceuticals Q2 2025 Earnings Report

Acurx Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.10
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Acurx Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Acurx Pharmaceuticals Announcement Details

• Quarter: Q2 2025
• Date: 8/8/2025
• Time: Before Market Opens
• Conference Call Date: Friday, August 8, 2025
• Conference Call Time: 8:00AM ET

Acurx Pharmaceuticals (NASDAQ:ACXP) is a clinical-stage biotechnology company dedicated to the discovery and development of novel anti-infective therapies aimed at addressing the growing threat of antimicrobial resistance. Founded in 2018 and headquartered in Durham, North Carolina, Acurx focuses on therapeutic approaches that target critical bacterial mechanisms, with the goal of delivering safe and effective treatments for both community- and hospital-acquired infections.

The company’s lead program is an oral therapy designed to selectively inhibit DNA polymerase IIIC, a key enzyme in Clostridioides difficile, which represents a significant cause of healthcare-associated diarrhea. Acurx’s second major asset comprises a series of proprietary β-lactamase inhibitors intended to restore the potency of existing β-lactam antibiotics against multidrug-resistant gram-negative pathogens. These candidates have advanced through preclinical and early clinical stages, demonstrating the potential to address urgent medical needs where few treatment options exist.

Acurx has established collaborations with academic research institutions and non-profit organizations to accelerate its pipeline. The company participates in government-funded initiatives focused on antibiotic innovation and maintains strategic partnerships to support global development and eventual commercialization. While its primary operations are in the United States, Acurx is actively exploring licensing agreements and joint ventures to expand its reach into Europe and Asia.

The leadership team at Acurx Pharmaceuticals combines deep expertise in infectious disease research, clinical development, and regulatory affairs. Its executive management includes a Chief Executive Officer with more than 20 years of experience in pharmaceutical research and development, a Chief Medical Officer who has overseen multiple antibiotic clinical trials, and a Board of Directors comprised of seasoned scientists and industry veterans. Together, they guide Acurx’s mission to deliver next-generation therapies that combat resistant infections and improve patient outcomes.